Quest Diagnostics®
Is it flu, COVID-19, RSV, or something else?
The combination of seasonal flu, the COVID-19 pandemic, and the rising rates of Respiratory Syncytial Virus (RSV)1 can make a differential diagnosis challenging when your patients experience fever, cough, shortness of breath, or other symptoms. That’s because these symptoms are common in a wide variety of respiratory illnesses.  

Molecular respiratory syndromic panels from Quest Diagnostics—including our new SARS-CoV-2 (COVID-19) + Influenza A/B, Respiratory Syncytial Virus (RSV) Panel—provide accurate, rapid results when you need to know.
Clinicians are encouraged to consider testing for other viral causes of respiratory illness, for example, influenza, in addition to testing for SARS-CoV-2.2
Whether caused by influenza A/B, SARS-CoV-2 (COVID-19), or another respiratory illness, the symptoms can be very similar3:
Precise diagnoses are especially important today for children, older adults, pregnant women, and people with underlying conditions or compromised immune systems so you can more quickly determine the best treatment path.

Quest Diagnostics offers the convenience of testing for influenza A and B and other respiratory pathogens in conjunction with testing for SARS-CoV-2 (COVID-19) to help you rapidly identify the pathogen causing your patient’s illness.
Our molecular respiratory syndromic panels can help:
  • Determine if symptoms are due to a viral or bacterial infection
  • Identify the pathogen for a more accurate diagnosis, to inform more effective treatment
  • Diagnose infections that may have been commonly missed, due to a lack of clinical suspicion or available routine testing4
  • Avoid prescribing antibiotics when they are not necessary
Avoid antibiotic misuse

The CDC recommends changes to the way antibiotics are used to combat a growing public health issue.5
Make a precise diagnosis with molecular testing
For acute respiratory tract infections, timely clinical decision-making is crucial. Molecular respiratory syndromic panels from Quest Diagnostics provide accurate, rapid results for diagnosis of influenza A/B, RSV, SARS-CoV-2, and other viruses or bacterial infections.
  • Rapid turnaround time (24–48 hours)
  • Shorten time to diagnosis compared to that of traditional culture methods4
  • Help prevent the spread of contagious illnesses
  • Make informed decisions regarding infection control measures and timely outbreak investigations4
The preferred way to test

Evidence is increasing that molecular viral panel tests are preferable to traditional virus detection methods (eg, culture, rapid antigen detection test, direct fluorescent antibody).6

Molecular viral panels offer6
Whether you suspect a viral or bacterial infection, our respiratory testing panels detect viral and bacterial pathogens to help you make the most accurate diagnosis.
Molecular offerings and panels for respiratory pathogen testing Test code CPT code(s)
New: SARS-CoV-2 RNA (COVID-19), Influenza A/B and RSV RNA, Qualitative NAAT
39816 0241U

Human RSV A
Human RSV B
Influenza A
Influenza B
SARS-CoV-2

SARS-CoV-2 RNA Qualitative NAAT (COVID-19) 39448 87635 (HCPCS:U0003)

SARS-CoV-2
SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT 31688 87636

Influenza A
Influenza B
SARS-CoV-2

SARS-CoV-2 RNA (COVID-19) and Respiratory Viral Panel, Qualitative NAAT 31686 87635 (HCPCS: U0003), 87633

Adenovirus
Human Metapneumovirus (HMPV)
Human Parainfluenza Virus (HPIV) 1
Human Parainfluenza Virus (HPIV) 2
Human Parainfluenza Virus (HPIV) 3
Human RSV A
Human RSV B
Influenza A
Influenza A Subtypes H1
Influenza A Subtypes H3
Influenza B
Rhinovirus/Enterovirus
SARS-CoV-2

SARS-CoV-2 RNA (COVID-19) and Respiratory Pathogen Panel, Qualitative NAAT 31687 87635 (HCPCS: U0003), 87633, 87486, 87581

Adenovirus
Human Metapneumovirus (HMPV)
Human Parainfluenza Virus (HPIV) 1
Human Parainfluenza Virus (HPIV) 2
Human Parainfluenza Virus (HPIV) 3
Human Parainfluenza Virus (HPIV) 4
Human RSV A
Human RSV B
Influenza A
Influenza A Subtype H1
Influenza A Subtype H3
Influenza B
Rhinovirus/Enterovirus
Bocavirus
Coronavirus 229E
Coronavirus OC43
Coronavirus NL63
Coronavirus HKU1
Chlamydophila pneumoniae
Mycoplasma pneumoniae
 SARS-CoV-2

Molecular respiratory pathogen tests and panels (non-COVID) Test code CPT code(s)
Influenza A or B, RNA Qualitative RT-PCR 16086 87502

Influenza A
Influenza B

Respiratory Syncytial Virus (RSV) RNA, Qualitative Real-Time PCR 16047 87634

Human RSV A
Human RSV B

Influenza A and B and RSV RNA, Qualitative, Real-Time RT-PCR 91989 87631

Human RSV A
Human RSV B
Influenza A
Influenza B

Respiratory Viral Panel (RVP) 95512 87633

Adenovirus
Human Metapneumovirus
Human Parainfluenza Virus (HPIV) 1
Human Parainfluenza Virus (HPIV) 2
Human Parainfluenza Virus (HPIV) 3
Human RSV A
Human RSV B
Influenza A
Influenza A Subtype H1
Influenza A Subtype H3
Influenza B
Rhinovirus/Enterovirus

Respiratory Pathogen Panel (RPP) 37444 87633, 87486 (C pneumoniae), 87581 (M pneumoniae)

Adenovirus
Human Metapneumovirus (HMPV)
Human Parainfluenza Virus (HPIV) 1
Human Parainfluenza Virus (HPIV) 2
Human Parainfluenza Virus (HPIV) 3
Human Parainfluenza Virus (HPIV) 4
Human RSV A
Human RSV B
Influenza A
Influenza A Subtype H1
Influenza A Subtype H3
Influenza B
Rhinovirus/Enterovirus
Bocavirus
Coronavirus 229E
Coronavirus OC43
Coronavirus NL63
Coronavirus HKU1
Chlamydophila pneumoniae
Mycoplasma pneumoniae

Components of panels can be ordered separately. Components available individually include Adenovirus DNA, Qualitative, Real-Time PCR (Test Code 16046); Influenza A and B Virus with Subtyping, Real-Time PCR (Test Code 91335); Parainfluenza Virus (Types 1, 2, 3 and 4) RNA, Qualitative, Real-Time PCR (Test Code 91228), Rhinovirus RNA, Real-Time PCR (Test Code 40035); Enterovirus RNA, Qualitative, Real-Time PCR (Test Code 15082); Human Metapneumovirus RNA, Qualitative, Real-Time PCR (Test Code 40034); Chlamydophila pneumoniae DNA, Qualitative, Real-Time PCR (Test Code 16003); Mycoplasma pneumoniae DNA, Qualitative, Real-Time PCR (Test Code 15498).
Visit our test directory to learn more about our complete portfolio of respiratory infection tests.
New testing options use a single specimen to cotest for SARS-CoV-2 and other respiratory pathogens, which helps expedite diagnosis so you can develop an appropriate treatment/care plan.
Leadership

A diagnostic leader during global health crises, Quest introduced a COVID-19 test 2 days before the virus was labeled a worldwide pandemic. Our 47,000 passionate employees continue to deliver diagnostic insights to support the effort to fight COVID-19.
Convenience

Labs available nationwide to support increased testing volume including blood specimen collection in over 2,250 Patient Service Centers; integration with most EHRs through Quanum® Lab Services Manager.
History and expertise

Four decades of experience leading infectious disease testing during public health emergencies, and hundreds of experts available to help interpret test results.
There are often a lot of questions when it comes to testing for influenza and other respiratory illnesses—more so today with the complications of the COVID-19 pandemic. Please complete the form below for a sales representative to contact you to discuss the benefits of cotesting, or to help you select the right test for your patients.
* Required fields
  •  The Cepheid SARS-CoV-2, Influenza A/B and RSV test, the cobas® SARS-CoV-2 & Influenza A/B Test and the Quest SARS-CoV-2 RT-PCR test and other molecular tests (“Tests”) have not been FDA cleared or approved.
  • The Roche® test has been authorized only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.
  • The Cepheid SARS-CoV-2, Influenza A/B and RSV test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens; 
  • The Cepheid SARS-CoV-2, Influenza A/B and RSV test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
  • The Roche test is only authorized for the duration of the declaration that circumstances exist justifying the authorized of the emergency use of in vitro diagnostics for detection and differentiation of SARS-CoV-2 virus, Influenza A, and Influenza B under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorized is terminated or revoked sooner. 
  • The Tests have been authorized by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests. 
  • The Quest test and other molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
  • The Quest test and other molecular tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Test codes may vary by location. Please contact your local laboratory for more information.

The CPT® codes provided are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

References
  1. CDC. RSV national trends. Updated August 25, 2021. Accessed August 26, 2021. https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html
  2. CDC. Interim clinical guidance for patients with confirmed Coronavirus disease (COVID-19). Updated February 16, 2021.https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
  3. CDC. Similarities and differences between flu and COVID-19. Reviewed August 31, 2020. Accessed September 24, 2020. https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm
  4. Ramanan P, Bryson A, Binnicker MJ, et al. Syndromic panel-based testing in clinical microbiology. Clin Microbiol Rev. 2017;31(1):e00024-17. doi:10.1128/CMR.00024-17
  5. CDC. About antibiotic resistance. Updated March 13, 2020. Accessed December 1, 2018. https://www.cdc.gov/drugresistance/about.html
  6. Ginocchio CC, McAdam AJ. Current best practices for respiratory virus testing. J Clin Microbiol. 2011;49(9 Suppl):S44-S48. doi:10.1128/JCM.00698-11
Image content features a model and is intended for illustrative purposes only.
Terms of Use  |  Privacy Notices  |  Contact Us  |  QuestDiagnostics.com  | Privacy Shield | Your Privacy Choices

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2022 Quest Diagnostics Incorporated. All rights reserved.